[go: up one dir, main page]

UY33495A - Derivados de bisaril (tio)morfolina como moduladores s1p - Google Patents

Derivados de bisaril (tio)morfolina como moduladores s1p

Info

Publication number
UY33495A
UY33495A UY33495A UY33495A UY33495A UY 33495 A UY33495 A UY 33495A UY 33495 A UY33495 A UY 33495A UY 33495 A UY33495 A UY 33495A UY 33495 A UY33495 A UY 33495A
Authority
UY
Uruguay
Prior art keywords
derivatives
bisaril
morfolina
modulators
tio
Prior art date
Application number
UY33495A
Other languages
English (en)
Inventor
Bakker Wouter I Iwema
Bronger Raymond
Original Assignee
Abbot Healthcare Products B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbot Healthcare Products B V filed Critical Abbot Healthcare Products B V
Publication of UY33495A publication Critical patent/UY33495A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La presente invención se relaciona con derivados de bisaril (tio) morfolina de la fórmula (I). Los compuestos de la invención tienen afinidad con los receptores S1P y se pueden utilizar en el tratamiento, alivio o prevención de enfermedades y afecciones medidas por el receptor S1P.
UY33495A 2010-07-09 2011-07-08 Derivados de bisaril (tio)morfolina como moduladores s1p UY33495A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10169108 2010-07-09
EP11158269 2011-03-15

Publications (1)

Publication Number Publication Date
UY33495A true UY33495A (es) 2012-01-31

Family

ID=44323383

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33495A UY33495A (es) 2010-07-09 2011-07-08 Derivados de bisaril (tio)morfolina como moduladores s1p

Country Status (13)

Country Link
US (3) US9029371B2 (es)
EP (1) EP2590954B1 (es)
JP (1) JP5841593B2 (es)
CN (1) CN103080096B (es)
AR (1) AR082137A1 (es)
CA (1) CA2804329C (es)
DK (1) DK2590954T3 (es)
ES (1) ES2570744T3 (es)
MX (1) MX338605B (es)
PL (1) PL2590954T3 (es)
TW (1) TW201206893A (es)
UY (1) UY33495A (es)
WO (1) WO2012004375A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522361B (zh) * 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
US8802673B2 (en) * 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
EP2802578B1 (en) * 2012-01-12 2015-10-07 F.Hoffmann-La Roche Ag Heterocyclic derivatives as trace amine associated receptors (taars)
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
BR112022008113A2 (pt) 2019-10-31 2022-07-19 Escape Bio Inc Formas sólidas de um modulador de receptor s1p

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069387A1 (ru) 1982-07-01 1985-11-30 Институт физико-органической химии и углехимии АН УССР Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием
GB2228432A (en) 1989-01-13 1990-08-29 Grayston Central Services Multi-role machine for heating and coating pipe welds.
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
JP2681589B2 (ja) 1992-12-28 1997-11-26 日揮株式会社 配管溶接継手の熱処理方法
JPH072848A (ja) 1993-04-23 1995-01-06 Sankyo Co Ltd モルホリンおよびチオモルホリン誘導体
GB9522845D0 (en) 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
JP3822680B2 (ja) 1996-08-30 2006-09-20 新日本製鐵株式会社 誘導加熱された接合部の冷却方法および冷却装置
JP4518587B2 (ja) * 1998-03-09 2010-08-04 興和創薬株式会社 ２−フェニルモルホリン誘導体
PL203161B1 (pl) 2000-04-21 2009-08-31 Shionogi & Co Pochodne oksadiazolu, kompozycja farmaceutyczna je zawierająca oraz zastosowanie pochodnej oksadiazolu do wytwarzania leku do leczenia raka
FR2822727A1 (fr) 2001-04-03 2002-10-04 Gesal Ind Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement
JP3649223B2 (ja) 2003-01-08 2005-05-18 株式会社日立製作所 配管系の熱処理方法および熱処理装置
US7842689B2 (en) * 2003-06-12 2010-11-30 Btg International Limited Cyclic hydroxylamine as psychoactive compounds
JP4861177B2 (ja) 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
KR100943555B1 (ko) * 2004-04-30 2010-02-22 워너-램버트 캄파니 엘엘씨 중추신경계 장애를 치료하기 위한 치환된 모르폴린 화합물
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
JP4491334B2 (ja) 2004-12-01 2010-06-30 日立Ｇｅニュークリア・エナジー株式会社 配管の熱処理方法および装置
JP4599250B2 (ja) 2005-08-10 2010-12-15 株式会社東芝 高周波誘導加熱時外面温度制御方法および当該制御装置
JP2007063642A (ja) 2005-09-01 2007-03-15 Hitachi Ltd 残留応力改善方法と高周波誘導加熱用コイル
EP1989188B1 (en) 2006-02-28 2015-07-22 Dart Neuroscience (Cayman) Ltd Therapeutic piperazines as pde4 inhibitors
US20100009969A1 (en) 2006-07-27 2010-01-14 Ucb Pharma, S.A. Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands
WO2008028937A1 (en) 2006-09-08 2008-03-13 Novartis Ag N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
CL2007003784A1 (es) 2006-12-21 2008-06-27 Abbott Lab Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
BRPI0806932A2 (pt) * 2007-02-02 2014-05-06 Novartis Ag Antagonista do receptor s1p1 de cromeno
JP5191497B2 (ja) 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ，インコーポレイテッド Ｓ１ｐ受容体調節化合物およびその使用
EP2148863A1 (en) * 2007-04-23 2010-02-03 Novartis Ag Phthalazine and isoquinoline derivatives with slp receptor modulating activities
WO2009084501A1 (ja) 2007-12-27 2009-07-09 Asahi Kasei Pharma Corporation スルタム誘導体
EP2250176B1 (en) 2008-01-30 2012-08-01 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
AU2009209235B2 (en) 2008-01-30 2013-07-18 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands
US20090321144A1 (en) 2008-06-30 2009-12-31 Wyble Kevin J Protecting an element from excessive surface wear by localized hardening
AR077969A1 (es) * 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
SG182628A1 (en) 2010-02-04 2012-08-30 Esteve Labor Dr 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
CN101812058B (zh) 2010-04-13 2012-03-21 湖南大学 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用

Also Published As

Publication number Publication date
US20150191457A1 (en) 2015-07-09
MX2013000361A (es) 2013-04-29
DK2590954T3 (en) 2016-05-02
EP2590954A1 (en) 2013-05-15
CA2804329A1 (en) 2012-01-12
US20160151376A1 (en) 2016-06-02
WO2012004375A1 (en) 2012-01-12
AR082137A1 (es) 2012-11-14
TW201206893A (en) 2012-02-16
US20130203745A1 (en) 2013-08-08
JP2013531003A (ja) 2013-08-01
JP5841593B2 (ja) 2016-01-13
ES2570744T3 (es) 2016-05-20
US9662337B2 (en) 2017-05-30
PL2590954T3 (pl) 2016-09-30
EP2590954B1 (en) 2016-04-13
MX338605B (es) 2016-04-22
CN103080096A (zh) 2013-05-01
CN103080096B (zh) 2015-12-09
CA2804329C (en) 2019-05-14
US9227960B2 (en) 2016-01-05
US9029371B2 (en) 2015-05-12

Similar Documents

Publication Publication Date Title
UY33497A (es) Derivados de espiro-piperidina como moduladores s1p
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
UY32858A (es) Derivados de (tio)morfolina como moduladores de sip
ECSP15022555A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
UY33272A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
CR20150250A (es) Nuevos derivados de piridina
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
ECSP13013074A (es) Nuevos derivados de piridina
UY35395A (es) Inhibidores de bromodominios tetracíclicos
UA116467C2 (uk) Модулятори p2x7
UY33271A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
BR112014005234A2 (pt) tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas
CR20150204A (es) Nuevos derivados de piridina
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
UY34062A (es) ?compuestos heterocíclicos fusionados moduladores de canal ionico para el tratamiento de enfermedades que responden al bloqueo de canal de sodio?.
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
EA201692272A1 (ru) Модуляторы s1p
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
CU20170037A7 (es) Compuestos derivados de n-alquilaril-5-oxiaril-octahidro ciclopenta[c)pirrol moduladores alostéricos negativos de nr2b
UY33509A (es) Metodos y composiciones para el tratamiento de la alergia

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200807